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The goal of this thesis is to present the evidence for the role of NMDA receptor 
excitotoxicity in pathology of Alzheimer’s disease, epilepsy, major depressive disorder 
and ischemic stroke, evaluate the neuroprotective effects of NMDA receptor antagonists 
ketamine and memantine based on excitotoxicity research, and review the current body 
of evidence on their potential use as a treatment for these conditions. 
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Abstrakt 
Cílem této práce je prezentovat důkazy pro roli excototoxicity NMDA receptoru v 
patologii Alzheimerovy choroby, epilepsie, depresivní poruchy a ischemické mrtvice, 
zhodnotit neuroprotektivní účinky antagonistů NMDA receptorů ketaminu a memantinu 
na základě výzkumu excitotoxicity a posoudit současný soubor důkazů pro jejich 
potenciální využití v léčbě těchto nemocí. 
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Various neurological and mental disorders have been plaguing humanity throughout 
history.  Although most of these conditions are still somewhat shrouded in mystery today, 
we have gained some insight into the mechanisms behind these disorders. One such 
mechanism is NMDA receptor excitotoxicity, which plays a role in the pathophysiological 
processes leading to neurodegenerative diseases through increasing neuronal apoptosis 
and necrosis via increased Ca2+ influx. The following text aims to elucidate the basic 
mechanisms of NMDA receptor excitotoxicity and its role in Alzheimer’s disease, epilepsy, 
major depressive disorder and ischemic stroke and lay an argument for the therapeutic 
use of NMDA receptor antagonists. Ketamine and memantine are among the most 
thoroughly studied NMDA receptor inhibiting drugs to date and both are already widely 
used in medical practice. They both have been more or less extensively studied as 
potential treatment options for Alzheimer’s disease, epilepsy, major depressive disorder 

















2. Characteristics of NMDA receptors 
2.1. General 
NMDA receptors are a group of ionotropic glutamate receptors, occurring on the 
neuronal membranes. They are involved in several physiological and pathophysiological 
processes e.g. long-term potentiation, associated with memory formation and neural 
plasticity (Artola and Singer 1987) and excitotoxicity (Rothman and Olney 1987). 
2.2. Subunits 
The individual NMDA receptors are assembled into heterotetramers consisting of two 
obligatory GluN1 subunits and combination of two GluN2 or GluN3 subunits. The GluN1 
subunit occurs in a total of eight variants resulting from alternative splicing from a single 
gene. GluN2 occurs in four variants (A-D) and GluN3 in two variants (A, B). Each GluN2 
and GluN3 subunit variant is coded by a separate gene. (Traynelis et al. 2010) NMDARs 
are formed into GluN1/GluN2 or GluN1/GluN3 diheteromers (Sanz-Clemente et al. 2013; 
Traynelis et al. 2010) but can also occur as triheteromeric GluN1/GluN2A/GluN2B 
(Rauner and Köhr 2011) or GluN1/GluN2/GluN3A receptors (Sasaki et al. 2002). 
Different subunit combinations are present in different parts of the nervous system and 
vary during development having a unique function (Traynelis et al. 2010). The subunit 
composition of each NMDA receptor dictates its Ca2+ permeability, agonist/antagonist 
affinity, desensitization and deactivation periods. GluN2A containing NMDA receptors 
have the highest open probability, but the lowest glutamate affinity compared to the other 
subunit types. GluN2C, GluN2D and GluN3 all lower the Ca2+ permeability as well as 
sensitivity to Mg2+ and open channel blockers compared to GluN2A and GluN2B (Paoletti 
et al. 2013). 
2.3. Functional domains 
All types of GluN subunits show high structural homology and consist of the same four 
functional domains connected by linkers that carry the conformational changes 
throughout the receptor.  The amino-terminal domain (ATD) and the ligand-binding 
domain (LBD) are extracellular. They both have a clamshell-like shape which is formed by 
two subdomains - S1 and S2 in LBD and R1 and R2 in ATD. The ATD has a role in the inter-
subunit connection, interaction with extracellular proteins, and also contains binding 
sites for Zn2+ and various drugs which in turn regulate the function of the receptor. The 
ligand binding domain as the name suggests contains binding sites for agonists. The 
transmembrane domain (TMD) is anchored in the membrane and forms the channel of 
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the NMDA receptor. It consists of three transmembrane helices (M1, M3, M4) and a return 
loop (M2). The pore of the channel is composed of the M3 helices, carrying the amino acid 
motif responsible for ion selectivity and the M2 loop, which contains the binding site for 
Mg2+ and open channel blocker inhibitors. The carboxy terminal domain (CTD) is located 
intracellularly and interacts with several associated proteins (Traynelis et al. 2010). 
 
Figure 1: Simplified cross section of NMDA receptor showing GluN1 and GluN2 
subunits. a) binding site for L-glycine/D-serine b) binding site for L-glutamate/D-
aspartate c) binding site for Mg2+ and open channel blockers. (adopted from Traynelis et 
al. 2010; edited) 
2.4. Activation and functional properties 
The mechanism of activation was deduced after investigating these mechanisms in 
related channels from the glutamate receptor family (AMPA, kainate) due to the strong 
homology of key structures, but since then, many studies examined the properties of 
NMDA receptor itself (Ladislav 2018). To open the channel, binding of L-glycine or D-
serine to the LBD of each GluN1 subunit and L-glutamate, D-aspartate or NMDA to the 
LBD of the GluN2 subunit (or another L-glycine in case of the GluN3 subunit containing 
variant) is required (Patneau, Mayer 1990; Chatterton et al. 2002). After ligand binding, 
the S2 domain is bend towards the S1, closing the clamshell structure and causing 
conformational changes carried by linkers to the TMD and subsequent channel opening 
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and the flow of ions such as Na+, K+ and Ca2+ through the pore. NMDA receptor function is 
also regulated by Mg2+ voltage-dependent block. Many glutamate-activated synapses 
work with glutamate receptors in tandem, meaning that the membrane is first 
depolarized by the activation of a non-NMDA receptor, which releases Mg2+ from its 
binding site within the NMDA receptor channel, allowing the flow of cations (Ladislav 
2018). 
2.5. Basic antagonist pharmacology 
There are three types of NMDA receptor inhibitors, competitive inhibitors that bind to 
the ligand binding domain and don’t allow the agonist to bind, allosteric inhibitors that 
change the steric conformation of the NMDA receptor and uncompetitive inhibitors (open 
channel blockers) that bind directly into the channel of NMDA receptor. Ketamine and 
memantine are both mainly uncompetitive antagonists, but can also modify the NMDA 
















3. Role of NMDA receptors in excitotoxicity  
As stated earlier, NMDA receptors play a role in phenomenon known as NMDA 
excitotoxicity. The term first used by J.W. Olney in the early 1970s (Olney 1971), however, 
the toxic effects of high doses of glutamate were already observed by T. Hayashi in 1954 
(Hayashi 1954). At that time no connection between excitotoxicity and NMDA receptors 
was made since they weren´t yet discovered. The mechanism of excitotoxicity itself was 
described later, after the discovery, that NMDA receptors are permeable for Ca2+ 
(MacDermott et al. 1986). Ca2+ is an important second messenger in several cascades, and 
cell death is one of them (Schanne et al. 1979). In cases where NMDA receptor channels 
are more active than is physiologically normal, the intracellular concentration of Ca2+ ions 
increases, which in turn triggers processes leading to cell death. This can be a result of 
pathogenic mutations or pathological processes in the body making the NMDA receptors 
more easily activated, staying open for long periods, or being expressed on the cell surface 
in larger numbers than in healthy individuals (XiangWei, Jiang, and Yuan 2018). Another 
reason for NMDA receptor hyperactivity can be simply too high concentrations of its 
agonists, arising from another pathological state, such as in the case of stroke and brain 
injury or administration of certain drugs (Castillo, Dávalos, and Noya 1997). It is then 
logical to predict that pharmacological inhibition of such hyperactivated receptors can 
alleviate the pathological manifestations of some neurological disorders caused by 
increased neuronal death due to NMDA receptor excitotoxicity. Studies have shown 
improved neuronal survival of excitotoxic insult when treated with NMDA receptor 
antagonists (Choi, Koh, and Peters 1988). Note, that not all NMDA receptors are equal in 
their excitotoxic effects. NMDA receptor localization and subunit composition 
determining the pathways they trigger upon activation. NMDA receptors containing the 
GluN2B subunit tend to be localized more on the extrasynaptic membrane and seem to be 
the dominant culprit when it comes to NMDA receptor-related excitotoxicity, but there is 





4. Role of excitotoxicity in selected neurological and mental 
diseases 
4.1. Alzheimer’s disease 
The cause of Alzheimer’s disease has long been a mystery to science, but in the last 
few decades many plausible mechanisms have been proposed and glutamate 
excitotoxicity is among them. A dysregulation in glutamate transporters and receptors 
and subsequent impaired extracellular glutamate clearing have been found in Alzheimer’s 
patients (Jacob et al. 2007). Beta-amyloid plaques, another studied factor in AD was also 
connected to increased excitotoxicity (Koh, Yang, and Cotman 1990). The connection 
between glutamate excitotoxicity and Alzheimer’s disease was thoroughly reviewed by 
Hynd et.al. in Neurochemistry 2004 (Hynd, Scott, and Dodd 2004). 
4.2. Epilepsy 
It has been shown that impaired NMDA receptor signaling plays a substantial role in 
the epileptic episodes. In epilepsy models, there is evidence for increased concentrations 
of extracellular glutamate (Soukupova et al. 2015). Moreover, the normal expression of 
glutamate transporters seems to be disrupted in epilepsy (Hubbard et al. 2016). Many 
patients that suffer from frequent epileptic seizures have been diagnosed with a form of 
NMDAR mutation which can increase neuron susceptibility to excitotoxic events by 
changing the NMDA receptor sensitivity to agonists and channel open probability 
(Sibarov et al. 2017). These NMDA receptor signaling impairments are perfect conditions 
for the development of excitotoxic neuronal damage which often leads to other 
neurological and cognitive impairments in epilepsy patients. 
4.3. Major depressive disorder 
For a long time, monoamine disruption was the main theory behind the mechanism of 
depression development, but recently more evidence for the role of glutamate has come 
to light.  A meta-analysis of brain imaging studies found a significant volumetric reduction 
of either certain brain regions or even total cerebral volume in patients diagnosed with 
depression (Koolschijn et al. 2009), which in conjunction with dysregulations of 
glutamate reuptake systems (Niciu et al. 2014) point to excitotoxicity possibly playing a 
role in treatment-resistant depression. Similar claims of this connection have already 
been made in review papers discussing the glutamate hypothesis of depression (Sanacora, 
Treccani, and Popoli 2012). 
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4.4. Ischemic stroke 
According to the World Health Organization statistics, ischemic stroke is among 
leading causes of death in developed countries. Its survivors are often struck with 
debilitating long-term effects caused by massive neuronal death in the oxygen-deprived 
brain. Although it cannot be held accountable for all the damage, NMDA receptor 
excitotoxicity seems to have a non-negligible role in stroke pathophysiology. Elevated 
levels of excitatory amino acids have been measured in animal and in vitro models as well 
as in actual stroke patients (Benveniste et al. 1984; Baker et al. 1991; Castillo, Dávalos, 
and Noya 1997; Kimura et al. 1998). In the case of progressing stroke, the excitatory 
amino acid concentrations stayed elevated up to 24 hours after onset (Dávalos et al. 
1997). One case report measured a 300-fold increase in extracellular levels of excitatory 
amino acids persisting up to 6 days after a massive stroke (Bullock et al. 1995). These 
findings show solid evidence for the role of NMDA receptor excitotoxicity in the pathology 
of ischemic stroke, further backed by in vitro hypoxia studies that linked neuronal damage 


















5.1. General characteristics 
Memantine is a medication of the adamantane class. It is widely used to treat 
Alzheimer’s and Parkinson’s disease. It was first synthesized by Eli Lily and Company in 
1968 as potential diabetes medication. After its mind-altering effects were discovered, 
research has focused on using it for treating Alzheimer´s disease, but it wasn´t until 1980 
that its interaction with NMDA receptors came to light.  
5.2. NMDA receptor inhibition 
There are two direct ways and one indirect way how memantine inhibits the NMDA 
receptors’ activity. Memantine binds directly into two distinct binding sites. First is 
located in directly into the ion channel pore and block NMDA receptors in a use-
dependent block manner, same way as ketamine does (Schmitt, Ryan, and Cooper 2007). 
Memantine can also bind to a site located in the ligand-binding domain and cause 
allosteric inhibition (Glasgow, Wilcox, and Johnson 2018). There is also evidence that 
memantine when applied to rodent brain slices increases the production of kynurenic 
acid, an endogenous NMDAR antagonist (Kloc et al. 2008). This indirect effect of 
memantine can be the third route of NMDA receptor inhibition. Memantine has lesser 
affinity for NMDA receptors compared to other antagonists, so it is more suitable for 
certain treatments since it allows for some level of physiological NMDAR activity to 
persist (Rammes, Danysz, and Parsons 2008). 
5.3. In vitro studies 
A large body of evidence for memantine’s neuroprotectivity in vitro has been 
accumulated throughout the 1990s and early 2000s. Most of the studies share a similar 
methodic of applying memantine and NMDA receptor agonists to neuronal cultures, with 
the only differences being the types of neuronal culture used, different memantine and 
agonist concentrations, and times of memantine application. Despite the minor 
methodical differences, all the studies presented similar results. All cultures treated with 
memantine had significantly more surviving cells after the insult than those without 
treatment (Erdö and Schäfer 1991; Volbracht et al. 2006). A different approach was 
chosen in another study, where rat cortical neurons were plated on a microelectrode 
array and their firing patterns were recorded. The study found that memantine 
application preserved the synchronized firing of neuronal networks after glutamate insult 
(Kutzing, Luo, and Firestein 2012). Apart from studies focused on direct glutamate insult, 
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memantines potential to protect neurons exposed to beta-amyloid peptide was also 
examined. Although memantine was effective at decreasing neuronal damage, it did not 
affect beta-amyloid clearance or decreasing extracellular glutamate hyper-release (Song 
et al. 2008). 
5.4. Animal studies 
5.4.1. Artificial excitotoxicity experiments 
After successfully proving memantine’s anti-excitotoxic ability in vitro, research 
shifted focus to animal models. Although different methods of inducing glutamate-
induced excitotoxicity were deployed, all animal groups injected with memantine showed 
a significant reduction in neuronal loss compared to those without treatment. In one 
study, they repeatedly injected rats with different compound cocktails intraperitoneally 
or intravitreally for three weeks. Injections consisted of either pure low dose glutamate, 
low dose glutamate with memantine and control groups got saline or low dose 
memantine. Rats given memantine together with glutamate retained more healthy 
systemic and retinal neural tissue, compared to the control group injected with glutamate 
only. The group treated with only memantine without inducing excitotoxic insult by 
glutamate exhibited no difference compared to the group injected with only saline 
(Vorwerk et al. 1996). A very different approach was chosen in another study, where 
supraphysiological glutamate concentrations were induced by methylmercury injections. 
Here again, the group injected with memantine prior to methylmercury administration 
had a better outcome in terms of less neuronal damage and fewer morphological 
malformations of the cortex. However, memantine had no effect on reducing the excess 
glutamate and it seems it might have negatively affected the mercury clearing since the 
treated group had slightly higher mercury levels in the brain when compared to the 
untreated group (W. Liu et al. 2013). These studies however focused only on the 
histological side of treatment and didn’t take memantine’s cognitive effects into account. 
5.4.2. Alzheimer’s disease 
Since the discovery of the role of beta-amyloid in Alzheimer’s disease, many 
treatment options were studied in this context and memantine is no exception. Two main 
approaches were used in the studies. In the first approach, they directly injected beta-
amyloid into the brains of animals. In the second, they used transgenic animals expressing 
human presenilin-1 (PS1) and amyloid precursor protein (APP) which caused high 
production of beta-amyloid plaques. In the case of direct beta-amyloid injections, the 
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results were determined by histological examination of the brain slices. The groups 
treated with memantine had significantly less neuronal damage in their hippocampi 
compared to the animals who received no treatment (Miguel-Hidalgo et al. 2002; Colom 
et al. 2013). Although these results are very promising for memantine efficacy, simply 
injecting animals with beta amyloids does not fully simulate the whole complex of 
processes that undergo in Alzheimer patients. Also, the results only show decreased 
neuronal loss, but that does not mean there is no other damage to the functional structure 
of the neural tissue as a whole. The transgenic mice studies, on the other hand, 
implemented a variety of cognitive-behavioral tests which better reflect the overall 
outcome of memantine treatment. After a single oral dose of 5 mg/kg of memantine the 
transgenic mice exhibited substantial improvement in memory and cognitive 
performance, compared to other groups receiving either donepezil or no treatment 
(Nagakura et al. 2013). In another study both the transgenic and wild type mice received 
30 mg/kg memantine daily for four months. The transgenic group receiving memantine 
performed significantly better in the water maze test than their untreated transgenic 
counterparts. In this case, memantine had no apparent effect on the locomotor ability, 
exploration or aggression in neither transgenic nor wild type group (Minkeviciene, 
Banerjee, and Tanila 2004). One of the most thorough studies used mice expressing also 
human tau protein in addition to PS1 and APP and examined their performance in water 
maze test, object recognition test and passive inhibitory avoidance test. After consuming 
30 mg/kg memantine daily for three months the mice improved significantly their 
cognitive performance. Additionally, an immunohistochemical assay showed that 
memantine treatment successfully lowered the total beta-amyloid accumulation in the 
brains of the transgenic mice. Again, no apparent effect was noticed in healthy mice 
treated with memantine (Martinez-Coria et al. 2010). These results form a solid case for 
memantine’s efficacy in the treatment of Alzheimer’s disease. 
5.4.3. Ischemic stroke 
The administration of memantine was repeatedly proven able to reduce the impact 
of reversible ischemia in animal models, but the differences in experiment design and 
subsequent differences in results make it hard to compose a definitive resolution on its 
effectiveness in rodents. While all studies found a reduction of lesion size and neuronal 
damage, the dose-response varied substantially. One team saw the neuroprotective effect 
at dosages as low as 0.2 mg/kg, but 10 mg/kg was ineffective for others. Also, while one 
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behavioral study had successfully improved cognitive performance with doses of 20 
mg/kg, another study examining the histology of treated mice brains reported that this 
dose actually causes more neuronal damage (Block and Schwarz 1996). In another study, 
mice consuming 30 mg/kg memantine daily for 28 days after the induction of ischemia 
started improving their motor skills after the first 7 days of treatment (López-Valdés 
Héctor E. et al. 2014). One study found that daily subcutaneous injections of 20 mg/kg of 
memantine starting 3 days after ischemia induction and continued for 28 days improved 
mice’s performance in motor skill and spatial memory tests. An improvement was also 
noted in brain histology, notably improved plasticity and injury site remodeling and 
decreased atrophy. Biochemical assays found increased concentrations of brain-derived 
neurotrophic factor, glial cell line-derived neurotrophic factor, and vascular endothelial 
growth factor and reduced expression of GluN2B while GluN2A expression was increased. 
None of these effects were seen with 4 mg/kg daily doses (Wang et al. 2017). 
5.4.4. Depression 
With the advent of the glutamate hypothesis of depression memantine naturally 
came up as a potential treatment candidate. Both acute and chronic memantine 
administration in doses 5-20 mg/kg effectively reduced depression-like behavior in rats 
subjected to forced swimming. Additionally, acute administration of 20 mg/kg 
memantine increased brain-derived neurotrophic factor production in these rats (Réus et 
al. 2010). Another study subjecting the rats to chronic unpredictable stress while dosing 
them with 20 mg/kg memantine daily reported a reduction in depression-like behavior 
and also spatial memory impairment in treated animals, speculating it may be caused by 
dysregulated GluN2B expression (Quan et al. 2011). Memantine also reduced depression 
symptoms, improved stress tolerance and reduced neural apoptosis in mice after 
olfactory bulbectomy (Takahashi et al. 2018). 
5.4.5. Epilepsy 
Memantine has proven effective at reducing neuronal damage caused by pilocarpine-
induced status epilepticus when administered both before and after the seizure induction 
in rats. The effect was shown to be dose and time-dependent with higher doses given close 
to the seizure occurrence were the most effective (Zenki et al. 2018). Another study used 
lithium chloride and pilocarpine to induce seizures and deployed behavioral tests to 
quantify the cognitive impairment following the seizure. The rats showed signs of 
impaired spatial memory and orientation which were ameliorated in the group treated 
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with memantine (Kalemenev et al. 2016). On the other hand, memantine was shown to 
induce seizures in amygdala kindled rats, but this method is surrounded by a bit of 
controversy because although being a good model for studying the collateral effects of 
seizures in healthy animals, kindling is not thought to play a role in most epilepsy patients 
(Löscher and Hönack 1990; Bertram 2007).  
5.5. Clinical studies 
5.5.1. Stroke 
Two clinical studies on the use of memantine in recovering stroke patients have 
been completed so far. One of them was open-label, randomized, and placebo-controlled. 
They enrolled 53 patients admitted to the hospital with mild to moderate stroke within 
24 hours and divided them into two groups with roughly the same age, sex and 
comorbidity factor distribution. Both groups were treated according to the standard 
practice while one group received 20 mg memantine three times a day and the other 
placebo for a total of five days. The patients were scored according to the National 
Institute of Health Stroke Scale at the time of the admission and then every day of the 
duration of the study. In the end patients treated with memantine on top of standard 
treatment had improved their average NIHSS score by 2.96 compared to just 1.24 in the 
placebo group (Kafi et al. 2014). Another study looked at using memantine for the 
treatment of chronic poststroke aphasia. 28 patients have enrolled in the double-blind 
randomized phase of the study, where they received either 5 – 10 mg of memantine a day 
or a placebo for a total of 24 weeks. All patients were undergoing constraint‐induced 
aphasia therapy during this time. Both groups had improved their communicative 
abilities, but the one receiving memantine had a significantly better outcome. After that a 
24-week open-label phase continued and all patients received memantine. Here the 
former placebo group experienced greater improvement, but the effect was not as 
pronounced in the group who received memantine prior. This is probably due to 
established tolerance to the compound. This study does not directly show memantine’s 
anti-excitotoxic qualities, since there is no evidence for increased glutamate signaling 
several years after the stroke occurred, more likely, this stems from memantine’s neuro-
regenerative properties via brain-derived neurotrophic factor and other 
neuroregenerative factors increase (Berthier et al. 2009).  
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5.5.2. Alzheimer’s disease 
A meta-analysis from 2015 looking at 9 clinical memantine monotherapy studies 
with total of 2433 patients found a consistent improvement in all measured scales of 
cognition and quality of life compared to placebo without any serious side effects 
(Matsunaga, Kishi, and Iwata 2015). Another meta-analysis from 2017 examined 30 
clinical studies with total of 7567 patients consisting of monotherapy, combination with 
cholinesterase inhibitors and comparison studies. Here again memantine was assessed as 
successful at improving cognition and quality of life in all patients without causing any 
notable side effects (Kishi et al. 2017). 
5.5.3. Epilepsy 
A study done on epilepsy patients with memory dysfunction showed significant 
improvement in both the double-blind and subsequent open-label phase, however, the 
researchers speculated whether memantine was the main factor or the patients got better 
at solving the memory test due to acquired practice. Apart from memory, memantine also 
improved the general cognitive performance and overall quality of life (Leeman-
Markowski et al. 2018). Another study looked at 50 epilepsy patients with cognitive 
impairment. All patients were given 5 mg memantine a day for two months and their 
cognitive performance was frequently evaluated. Although memantine had no effect on 
seizure frequency or severity it did improve patients’ cognitive performance significantly, 
but these results should be taken lightly since the study didn’t include any placebo control 
(Solomatin et al. 2016). Memantine was also well tolerated when given to patients already 
treated with antiepileptic drugs and also managed to improve their cognition in phase III 
double-blinded placebo-controlled clinical trial (Marimuthu et al. 2016).  When compared 
with an acetylcholinesterase inhibitor donepezil, memantine provided greater cognitive 
and memory improvements for epilepsy patients at the same daily dose of 10 mg (Oustad 
et al. 2020). 
5.5.4. Depression 
Two studies found that memantine in doses 5 – 20 mg a day for 8 weeks or 10 – 20 mg 
for 12 weeks did not produce different outcome from placebo in patients diagnosed with 
major depressive disorder (Lenze et al. 2012; Zarate et al. 2006). But an open-label study 
using a progressive increase of dosage up to 40 mg a day found a significant reduction in 
depressive symptoms without major side effects (Ferguson and Shingleton 2007). One 
study examining the effects of memantine combined with escitalopram in patients with 
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geriatric depression found a greater increase in gray matter volume compared to 
escitalopram with placebo, but neither group had any changes in mood following the 




























6.1. General characteristics 
Ketamine is a dissociative anesthetic from the group of arylcyclohexylamines. 
Dissociative anesthesia refers to a state in which a person under the influence of a given 
anesthetic is still partially conscious and shows signs of alertness such as eye movement, 
but no reaction to pain. It was first synthesized by Calvin Lee Stevens in 1962 in search of 
possible alternatives to phencyclidine. During the first years of testing it was known as Cl-
581. Two enantiomers are available (R)-ketamine and (S)-ketamine, from which the latter 
exhibits a much greater affinity for NMDA receptors (Lodge, Anis, and Burton 1982). 
6.2. NMDA receptor inhibition 
Arylcyclohexanimes such as ketamine have a common binding site directly in the 
NMDA receptor channel, so their binding can only occur after the channel is opened. As in 
the case of Mg2+ inhibition, the change in membrane current pulls the positively charged 
ketamine molecule into the channel pore. The more NMDA receptor channels are 
activated on a given neuron the more ketamine can bind into them. This mechanism is 
referred to as the use-dependent block. The subsequent activation and opening of the 
NMDA receptor channel are also needed to release the arylcyclohexamines from the 
binding site, so the molecule may be "trapped" within the closed channel and dissociate 
only after the next activation which opens the ion channel. Apart from binding directly 
into the channel, ketamine can also bind to an allosteric site located on the intermembrane 
portion of the receptor and cause a drop in the open probability of NMDA receptors 
(Orser, Pennefather, and MacDonald 1997). 
6.3. Metabolism 
Ketamine is known to be turned into several metabolites after administration, some 
of which show varying levels of affinity for NMDA receptors themselves. This has to be 
taken into consideration whenever a study moves from in vitro to in vivo stage (Zanos et 
al. 2018). 
6.4. In vitro studies 
To date, ketamine’s neuroprotective qualities have been fairly well studied in vitro. 
Several studies confirmed ketamine’s ability to protect cultured neurons from glutamate-
induced excitotoxicity. Out of these, there are two that laid the foundation for a lot of 
future ketamine-mediated neuroprotection research. One of them found that the 
introduction of ketamine to cultured cortical neurons exposed to supraphysiological 
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levels of extracellular glutamate had a net positive effect on their survival (Choi et al. 
1990).  In the other study, ketamine application to cultured hippocampal neurons made 
them more likely to survive the glutamate insult and axotomy. This study also compared 
the potency of the two ketamine isomers and found that (S)-ketamine is more 
neuroprotective than its counterpart (Himmelseher, Pfenninger, and Georgieff 1996). 
Interestingly, it seems that neuroprotective effect of ketamine is not only associated with 
protecting neurons from excess glutamate exposure by decreasing the opening of NMDA 
receptor. (S)-ketamine has been shown to upregulate the expression of 
neuroregenerative factors in vitro, however further examination is needed to prove this 
effect in vivo (Himmelseher et al. 2000) Ketamine was also successful in protecting 
neurons exposed to cyanide and hypoxic environment, which served as a basis for making 
it one of the candidates for treatment of ischemic stroke (Weiss, Goldberg, and Choi 1986).  
As good as this all sounds, there are some drawbacks when it comes to ketamine’s overall 
effect on neurons. A major one would be ketamine’s own inherent neurotoxicity especially 
in high doses or with frequent administration. When applied to cultured rat neurons, 
ketamine not only induced generation of reactive oxygen species, but also upregulated 
NMDA receptor expression in cells which is can be more detrimental for a brain with 
pathologically high levels of extracellular NMDA receptor agonists or otherwise increased 
Ca2+ inflow through these channels (F. Liu et al. 2013). However, it is possible to reduce 
this effect when ketamine is stacked together with other drugs such as thiopental sodium 
(Shibuta, Varathan, and Mashimo 2006). 
6.5. Animal studies 
6.5.1. Artificial excitotoxicity experiments 
So far only one animal study examining ketamine in the context of neuroprotection 
against NMDA receptor agonist insult has been made. In this study rats were injected with 
either NMDA to cause the excitotoxic event in the brain. Researchers found that a dose of 
180 mg/kg given up to two hours after, but not before NMDA injection was able to lessen 
the neuronal death in rats’ hippocampi. They also noted that dividing the total dose into 
several smaller ones worked better than if given all at once (Lees 1995). Ketamine was 
actually more studied in the context of its neurotoxicity rather than neuroprotective 
activity in animals. For this reason, scientists often look at studying ketamine as a 




Single subanesthetic doses of ketamine have been effective at acutely reducing 
depression behavior in mice subjected to chronic unpredictable stress, but the effects 
were short-lived and continuous treatment saw no benefit (Jiang et al. 2017). No anti-
depressive effect was exhibited in rats treated acutely nor continuously with anesthesia-
inducing doses (Popik et al. 2008). However, another study using both mice and rats 
found a significant acute improvement in depressive behavior after (S)-ketamine 
administration and even long-lasting effect after (R)-ketamine administration (Fukumoto 
et al. 2017). Another study suggested, that the anti-depressive effects might be age-
dependent since no effect was seen in juvenile mice (Nosyreva et al. 2014). A comparative 
study found that administration of GluN2B selective antagonist Ro-25-6981 or early 
growth response protein 1 (Erg-1) siRNA produced the same anti-depressive effects as 
ketamine in mice subjected to chronic unpredictable stress and therefore theorized that 
ketamine produces these effects through antagonizing GluN2B-containing NMDA 
receptors and subsequent regulation of Egr-1 expression (Zhang et al. 2018). Another 
study subjecting mice to chronic mild stress found increased expression of GluN1 in 
stressed mice, which was ameliorated by ketamine and their depression behavior was 
also reduced (Tang et al. 2015). 
6.5.3. Ischemic stroke 
Ketamine was quite thoroughly studied in animal models of ischemic stroke with 
mixed results. One of the first experiments was carried out in 1987 on Mongolian gerbils 
whose brains are especially vulnerable to carotid blockade. The researchers found that 
injecting the gerbils with 100, 150, and 200 mg/kg of ketamine before inducing ischemia 
reduced the number of deaths compared to the animals anesthetized by ether before the 
procedure. Histopathological examination of the brains was carried out after sacrificing 
the recovered animals. The groups treated with ketamine had retained significantly more 
healthy neurons than the untreated in a dose-dependent manner (Marcoux, Goodrich, and 
Dominick 1988). Another study saw no benefit from injecting rats with 10 mg/kg before 
and after inducing ischemia but bringing the total dose up to 200 mg/kg divided into 
several doses over 8 hours preserved more neurons in rats’ hippocampi (Church, Zeman, 
and Lodge 1988). On the other hand, in a study administering 24 mg/kg before inducing 
forebrain ischemia and then 120 mg/kg a day intramuscularly to rats for seven days, there 
was no difference in brain necrosis compared to the untreated group (Jensen and Auer 
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1988). One study used sodium fluoride injections instead of blood flow blockage to 
simulate ischemic conditions. They found that simultaneous injection of ketamine with 
sodium fluoride had no effect on mice survivability, but pretreating them with 150 mg/kg 
ketamine prolonged the survival time, however the mice still died after two hours (Vasilev 
et al. 1998). 
6.5.4. Alzheimer’s disease 
There are currently no animal nor clinical studies examining the use of ketamine 
in the treatment of Alzheimer’s disease. There are two main reasons why it is not 
considered a viable route to be worth examining. One being ketamine’s neurotoxic effects 
when taken chronically or in high doses and the other would be ketamine’s plethora of 
undesirable physical and mental side effects. Simply put, unless the patient enjoys being 
high on ketamine for the rest of their life it would likely have no positive effect on their 
quality of life but rather the opposite.  
6.5.5. Epilepsy 
In one study, seizures were induced in rats by intracranial application of bicuculline. 
A 10 mg/kg dose of ketamine was injected intraperitoneally 15 minutes before and then 
every 30 minutes the bicuculline application for a total of four hours. Although ketamine 
did not stop the seizures from occurring nor reduced the epileptiform EEG activity, it was 
effective at reducing the subsequent neuronal damage. 80% of animals treated with 
ketamine had no signs of necrosis in the brain, while all of the untreated ones did (Clifford, 
Zorumski, and Olney 1989).  Another study induced seizures by injecting rats with lithium 
chloride mixed with pilocarpine intraperitoneally. Here ketamine decreased the intensity 
and duration of status epilepticus and post epileptic anxiety. Apart from this, ketamine 
also reduced neuronal death by 85 - 100 % (Loss, Córdova, and de Oliveira 2012). 
6.6. Clinical studies 
6.6.1. Stroke 
Given the mixed results from rodent studies and the many known side effects of 
ketamine in dosages needed to induce neuroprotection, it never managed to move into a 
clinical phase of testing for stroke treatment and it is quite unlikely to ever be tested. 
6.6.2. Epilepsy 
A review examining 41 case studies of 248 refractory epilepsy patients reported 
ketamine to be highly effective at stopping the seizures in these patients, but no controlled 
clinical trials for the use of ketamine in epilepsy exist to date (Rosati, De Masi, and 
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Guerrini 2018).  Although it was not studied in the context of neuroprotection in epilepsy 
patients, the fact that ketamine can ameliorate the frequency and severity of seizures in 
some patients resistant to treatment, might mean it can also indirectly reduce the 
neuronal damage produced by the seizures.  
6.6.3. Depression 
A meta-analysis published in 2020 looked at 20 randomized placebo-controlled 
studies examining the anti-depressive effects of single-dose or repeated ketamine 
administration. They reported single dose of ketamine being effective at improving mood 
up to 7 days after administration and up to 3 weeks after repeated dosing (Kryst et al. 
2020). Two studies deploying brain imaging techniques reported that ketamine 
administration can reverse structural changes and volumetric loss in the brains of 




















7. Conclusions and discussion 
The current knowledge suggests that dysregulation of glutaminergic system and 
NMDA receptor dysfunction play a significant role in Alzheimer’s disease, epilepsy and 
ischemic stroke. For this reason, the study of NMDAR antagonists as treatment for these 
diseases is highly desirable.  
Memantine proved itself effective at improving the outcomes and quality of life in 
Alzheimer’s disease, epilepsy and stroke patients and at ameliorating the pathological 
processes in these diseases. However, it still falls short of being able to treat these diseases 
on its own, rather it makes a good supplement drug for already used therapies. Ketamine, 
on the other hand, was most effective only in vitro conditions, and apart from helping with 
controlling seizures in few cases of epilepsy, it got no further attention to be studied as a 
treatment for Alzheimer’s disease or ischemic stroke, which, given its undesirable effects, 
is quite understandable.  
 The glutaminergic hypothesis of depression is gaining attention in the scientific 
community partly thanks to the success of ketamine in recent clinical trials, but since 
memantine failed to replicate these results it is more likely that ketamine’s anti-
depressant effect comes from affecting a different pathway. However, ketamine's ability 
to reverse structural changes in the depressed brain may come from preventing 
excitotoxicity and is responsible for the long duration of the anti-depressant effects.  
Overall, ketamine and memantine are both very interesting and important substances 
with a lot of potentials. Rationally developed memantine and ketamine derivatives can 
suppress side effects and open a new way in the treatment of neurological and mental 
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